IL279972A - Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment - Google Patents

Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment

Info

Publication number
IL279972A
IL279972A IL279972A IL27997221A IL279972A IL 279972 A IL279972 A IL 279972A IL 279972 A IL279972 A IL 279972A IL 27997221 A IL27997221 A IL 27997221A IL 279972 A IL279972 A IL 279972A
Authority
IL
Israel
Prior art keywords
substituted
unsubstituted
linear
branched
heterocyclic ring
Prior art date
Application number
IL279972A
Other languages
English (en)
Hebrew (he)
Original Assignee
Anima Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anima Biotech Inc filed Critical Anima Biotech Inc
Priority to IL279972A priority Critical patent/IL279972A/en
Priority to AU2022205591A priority patent/AU2022205591A1/en
Priority to JP2023540948A priority patent/JP2024502106A/ja
Priority to CN202280009131.9A priority patent/CN116635028A/zh
Priority to PCT/US2022/011203 priority patent/WO2022150316A1/en
Priority to CA3199333A priority patent/CA3199333A1/en
Priority to IL303320A priority patent/IL303320A/en
Priority to EP22737002.0A priority patent/EP4274569A4/en
Priority to US17/856,998 priority patent/US20220370431A1/en
Publication of IL279972A publication Critical patent/IL279972A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL279972A 2021-01-05 2021-01-05 Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment IL279972A (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL279972A IL279972A (en) 2021-01-05 2021-01-05 Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment
AU2022205591A AU2022205591A1 (en) 2021-01-05 2022-01-05 C-myc mrna translation modulators and uses thereof in the treatment of cancer
JP2023540948A JP2024502106A (ja) 2021-01-05 2022-01-05 ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用
CN202280009131.9A CN116635028A (zh) 2021-01-05 2022-01-05 c-MYC mRNA翻译调节剂及其在治疗癌症中的用途
PCT/US2022/011203 WO2022150316A1 (en) 2021-01-05 2022-01-05 C-myc mrna translation modulators and uses thereof in the treatment of cancer
CA3199333A CA3199333A1 (en) 2021-01-05 2022-01-05 C-myc mrna translation modulators and uses thereof in the treatment of cancer
IL303320A IL303320A (en) 2021-01-05 2022-01-05 C-myc mrna translation modulators and uses thereof in the treatment of cancer
EP22737002.0A EP4274569A4 (en) 2021-01-05 2022-01-05 C-MYC mRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER
US17/856,998 US20220370431A1 (en) 2021-01-05 2022-07-03 C-myc mrna translation modulators and uses thereof in the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL279972A IL279972A (en) 2021-01-05 2021-01-05 Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment

Publications (1)

Publication Number Publication Date
IL279972A true IL279972A (en) 2022-08-01

Family

ID=82358087

Family Applications (2)

Application Number Title Priority Date Filing Date
IL279972A IL279972A (en) 2021-01-05 2021-01-05 Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment
IL303320A IL303320A (en) 2021-01-05 2022-01-05 C-myc mrna translation modulators and uses thereof in the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL303320A IL303320A (en) 2021-01-05 2022-01-05 C-myc mrna translation modulators and uses thereof in the treatment of cancer

Country Status (8)

Country Link
US (1) US20220370431A1 (https=)
EP (1) EP4274569A4 (https=)
JP (1) JP2024502106A (https=)
CN (1) CN116635028A (https=)
AU (1) AU2022205591A1 (https=)
CA (1) CA3199333A1 (https=)
IL (2) IL279972A (https=)
WO (1) WO2022150316A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010762A1 (en) * 2022-07-03 2024-01-11 Anima Biotech Inc. C-myc mrna translation modulators and uses thereof in the treatment of cancer

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12404283B2 (en) 2022-07-03 2025-09-02 Anima Biotech Inc. c-MYC mRNA translation modulators and uses thereof in the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3030982A1 (de) * 1979-08-21 1981-03-12 Yamanouchi Pharmaceutical Co., Ltd., Tokyo 2-phenylimidazo(2,1-b)benzothiazolderivate
WO2007109120A2 (en) * 2006-03-17 2007-09-27 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of disease
WO2019131656A1 (ja) * 2017-12-28 2019-07-04 政一 親泊 ベンゾチアゾイミダゾリル化合物を含有する小胞体ストレス調節剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464384A (en) * 1981-12-23 1984-08-07 Yamanouchi Pharmaceutical Co., Ltd. 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
WO1998006724A1 (en) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
CA2973739A1 (en) * 2015-02-03 2016-03-24 Active Biotech Ab Imidazo[2,1-b]thiazole and 5,6-dihydroimidazo[2,1-b]thiazole derivatives useful as s100-inhibitors
UY37866A (es) * 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
CN113710663A (zh) * 2019-02-19 2021-11-26 纳罗医疗公司 Myc家族原癌基因蛋白的调节剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3030982A1 (de) * 1979-08-21 1981-03-12 Yamanouchi Pharmaceutical Co., Ltd., Tokyo 2-phenylimidazo(2,1-b)benzothiazolderivate
WO2007109120A2 (en) * 2006-03-17 2007-09-27 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of disease
WO2019131656A1 (ja) * 2017-12-28 2019-07-04 政一 親泊 ベンゾチアゾイミダゾリル化合物を含有する小胞体ストレス調節剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALLEN-PETERSEN, BRITTANY L., AND ROSALIE C. SEARS., MISSION POSSIBLE: ADVANCES IN MYC THERAPEUTIC TARGETING IN CANCER., 31 December 2019 (2019-12-31) *
CHAO QI, SPRANKLE KELLY G., GROTZFELD ROBERT M., LAI ANDILIY G., CARTER TODD A., VELASCO ANNE MARIE, GUNAWARDANE RUWANTHI N., CRAM: "Identification of N -(5- tert -Butyl-isoxazol-3-yl)- N ′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1- b ][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, no. 23, 10 December 2009 (2009-12-10), US , pages 7808 - 7816, XP093286667, ISSN: 0022-2623, DOI: 10.1021/jm9007533 *
SAYERS, CARLY M., ET AL., IDENTIFICATION AND CHARACTERIZATION OF A POTENT ACTIVATOR OF P53-INDEPENDENT CELLULAR SENESCENCE VIA A SMALL-MOLECULE SCREEN FOR MODIFIERS OF THE INTEGRATED STRESS RESPONSE., 31 December 2013 (2013-12-31) *
SERER, MARIA INES, ET AL., A HIGH-THROUGHPUT SCREENING FOR INHIBITORS OF RIBOFLAVIN SYNTHASE IDENTIFIES NOVEL ANTIMICROBIAL COMPOUNDS TO TREAT BRUCELLOSIS., 31 December 2019 (2019-12-31) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010762A1 (en) * 2022-07-03 2024-01-11 Anima Biotech Inc. C-myc mrna translation modulators and uses thereof in the treatment of cancer
WO2024010761A1 (en) * 2022-07-03 2024-01-11 Anima Biotech Inc. C-myc mrna translation modulators and uses thereof in the treatment of cancer

Also Published As

Publication number Publication date
IL303320A (en) 2023-07-01
EP4274569A1 (en) 2023-11-15
JP2024502106A (ja) 2024-01-17
CN116635028A (zh) 2023-08-22
EP4274569A4 (en) 2024-12-04
AU2022205591A9 (en) 2024-02-08
CA3199333A1 (en) 2022-07-14
AU2022205591A1 (en) 2023-07-06
US20220370431A1 (en) 2022-11-24
WO2022150316A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
AU2022200741B2 (en) Aminothiazole compounds as c-Kit inhibitors
AU2022201082B2 (en) Benzimidazole compounds as c-Kit inhibitors
CA2976741C (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
WO2021202964A1 (en) Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of diseases associated with p13k modulation
ES2620119T3 (es) Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa
JP2019508467A (ja) 癌治療用の２−シアノイソインドリン誘導体
WO2021252555A1 (en) Collagen 1 translation inhibitors and methods of use thereof
US20220370431A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
TW202529754A (zh) Tyk2抑制劑及其用途
IL294527B1 (en) 3-Methylindole Derivatives as Collagen 1 Translation Inhibitors and Their Uses in the Treatment of Fibrosis and Other Disorders
ES3045034T3 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
US12404283B2 (en) c-MYC mRNA translation modulators and uses thereof in the treatment of cancer
AU2023305002A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
KR20260052915A (ko) Pi3k 저해제 및 이의 용도
WO2024052692A1 (en) Novel compounds as ck2 inhibitors